台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

PD01-03: Use of Cluster of Urinary Biomarkers for Identifying Interstitial Cystitis and Bladder Conditions in Women with Interstitial Cystitis/Bladder Pain Syndrome

2024-12-19 • 觀看: 766 • 回應: 0 • doc
PD01-02: Optimal Timing of Percutaneous Nephrostomy (PCN) in Patients with Upper Ureteral Stones and Urosepsis

2024-12-19 • 觀看: 801 • 回應: 0 • doc
PD01-01: Lessons learned from 101 urethroplasties for urethral strictures

2024-12-19 • 觀看: 764 • 回應: 0 • doc
0610_下午場_2.1_呂福全醫師

2024-12-18 • 觀看: 2 • 回應: 0 • embed
0610_下午場_1.6_周吟柔醫師

2024-12-18 • 觀看: 0 • 回應: 0 • embed
7. MRDapplication in cancer treatment from advanced to early stage_李宛珊 (2024.11.03)

2024-12-18 • 觀看: 0 • 回應: 0 • embed
6. Breakthrough in lung cancer treatment: peri-operative immunotherapy_夏德椿 (2024.11.03)

2024-12-18 • 觀看: 0 • 回應: 0 • embed
5. Revolutionizing breast cancer treatment: peri-operative immunotherapy_林季宏 (2024.11.03)

2024-12-18 • 觀看: 0 • 回應: 0 • embed
4. Immunotherapy novel combination and potential breakthrough therapy in HNSCC_Dr. Mei-Kim Ang (2024.11.03)

2024-12-18 • 觀看: 1 • 回應: 0 • embed
3. What can we expect in the future development of oncology pipelines beyondADC?_陳偉武 (2024.11.03)

2024-12-18 • 觀看: 1 • 回應: 0 • embed
2. How physicians collaboratewith industry for drug development?_吳尚儒 (2024.11.03)

2024-12-18 • 觀看: 1 • 回應: 0 • embed
1. Tsunami in oncology: development in ADC_Dr.Andrea Lauer (2024.11.03)

2024-12-18 • 觀看: 1 • 回應: 0 • embed

Prev
260
261
262
263
264
265
266
267
268
269
Next
/ 1264